Everolimus
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Everolimus. Everolimus is an mTOR inhibitor (mechanistic target of rapamycin). Fully referenced neurology checklist.
Mode of action
- Everolimus is an mTOR inhibitor (mechanistic target of rapamycin)
Indications
Locked: subscribe to see this section.
Dosing
Locked: subscribe to see this section.
Infectious side effects
Locked: subscribe to see this section.
Systemic side effects
Locked: subscribe to see this section.
References
- Curatolo P. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy. Pediatr Neurol 2015; 52:281-289.
- Krueger DA, Wilfong AA, Mays M, et al. Long-term treatment of epilepsy with everolimus in tuberous sclerosis. Neurology 2016; 87:2408-2415.
- Krueger DA, Wilfong AA, Holland-Bouley K, et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol 2013; 74:679-687.
- Samueli S, Abraham K, Dressler A, et al. Efficacy and safety of Everolimus in children with TSC-associated epilepsy-pilot data from an open single-center prospective study. Orphanet J Rare Dis 2016; 11:145.
- Wiegand G, May TW, Ostertag P, Boor R, Stephani U, Franz DN. Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option? Eur J Paediatr Neurol 2013; 17:631-638.
